Quality standard for licorice of different sources

doi:10.19803/j.1672-8629.20240286

Abstract

Abstract: Objective To analyze the problems with the quality of Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L., identify obstacles to development and offer solutions. Methods Through talks with enterprises, field investigation, literature research and studies on the quality standard for Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L., the status quo of the Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. industry in Xinjiang, the problems with pharmaceutical standards and opportunities of development were analyzed. Results The rate of defective Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. in the medicinal field was high by the content determination standard specified in the Pharmacopoeia of the People's Republic of China (2020 edition). However, the licorice of three sources contained flavonoids with pharmacological action, so liquiritin alone could not be used as an indicator of quality control. Conclusion It is recommended that the quality standard for Glycyrrhiza inflata Bat. and Glycyrrhiza glabra L. be revised to adopt various flavonoid components as the quality evaluation indexes of licorice so as to promote its cultivation in China.

Key words: licorice, Glycyrrhiza inflata Bat., Glycyrrhiza glabra L., liquiritin, quality, standard, origin

CLC Number:

YANG Le, SHAN Lianlian, WANG Yali, YAN Shunhua, ZHOU Gang, CHEN Jia, WEI Feng. Quality standard for licorice of different sources[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1025-1028.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240286

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I9/1025

References

[1] ZHOU DL, WANG M, FENG JL, et al.Study on differential metabolites of Glycyrrhiza uralensis Fisch. in different years based on extensive targeted metabonomics[J]. Journal of Pharmaceutical Analysis, 2024, 44(1): 144-157.
[2] BIAN YH, WANG L, ZHANG XY, et al.Current situation and technology improvement of licorice industry chain[J]. Journal of Tianjin University of Traditional Chinese Medicine(天津中医药大学学报), 2020, 39(1): 19.
[3] LI WB, LUO L, CUI J, et al.Research progress on genetic diversity of 3 medicinal glycyrrhiza[J]. Journal of Chinese Medicinal Materials(中药材), 2019, 42(2): 463-469.
[4] XU K, LU JH, LI X, et al.Composition and functions of soil bacterial communities of wild Glycyrrhiza uralensis Fisch. in habitats with different degrees of salinization[J]. Acta Microbiologica Sinica, 2024, 65(5): 1550-1556.
[5] ZHOU G, SHAN LL, WANG YL, et al.Present Situation and prospect of study on quality standard of ethnic medicine in Xinjiang[J]. Chinese Pharmaceutical Affairs(中国药事), 2024, 38(1): 28-34.
[6] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China: VolumeⅠ(中华人民共和国药典一部)[S]. Beijing: China Medical Science Press, 2020: 88-89.
[7] CHEN J, NIE LX, CHENG XL, et al.Qualitative and quantitative analysis of main characteristic components of Glycyrrhiza inflate Bat. with chemometrics[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(9): 826-830.
[8] CHEN J, NIE LX, DAI SY, et al.Multivariate statistical analysis of the difference in chemical components between glycyrrhizae radix et rhizoma derived from Glycyrrhiza glabra L. and G. inflata Bat. from Xinjiang[J]. Modern Chinese Medicine(中国现代中药), 2021, 23(12): 2088-2095.
[9] CHEN J, NIE LX, HU XR, et al.Differences of chemical compounds between Glycyrrhiza uralensis Fisch. and Glycyrrhiza glabra L. by UHPLC-Q-TOF-MS/MS[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(9): 954-958.
[10] HAN WW, ZHONG Q, ZHANG R, et al.Research progress of active constituents and their mechanism of action in Glycyrrhiza uralensis Fisch.[J]. Chemistry of Life(生命的化学), 2023, 43(12): 1956-1962.

[1]	LU De, XU Wenyan, LIU Jinxin, PEI Yusheng. Discussion and analysis of bacterial endotoxin problems in FDA warning letters [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 857-862.
[2]	SUN Li, XIE Bin, XU Yanqin. Research progress of sustained and controlled release preparations of Chinese medicine [J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 949-954.
[3]	YE Anping, WEI Xue, HUANG Mingyue, ZHANG Xianxie, MA Zengchun, GAO Yue. Roles of Yangwei Anshen decoction in improving sleep quality in mouse model of insomnia induced by chronic unpredictable stress [J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 771-775.
[4]	SUN Yue, HU Xinyue, LI Jing, ZHANG Wei, DING Xiaoli, ZHANG Hui, LIANG Chenggang. Quality evaluation of desmopressin tablets and injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 632-637.
[5]	DING Xiaoli, HU Xinyue, WANG Xuelei, SUN Yue, LI Jing, ZHANG Hui, Liang Chenggang, WANG Yan. Quality evaluation of insulin glargine injections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 644-650.
[6]	HU Xiaozhen, MA Lina, HE Ting, GU Yuanyuan, ZHAO Wei, ZHENG Changhui, YE Zuguang, CAO Junling. Literature research on ancient and modern literature of Dichroae Radix and Shu lacquer [J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 587-593.
[7]	ZHANG Chenxue, PEI Yusheng, CAI Tong. Research progress in bacterial endotoxin test methods for insoluble raw materials, excipients and preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 273-279.
[8]	ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294.
[9]	WANG Dandan, WANG Ying, YAO Lingwen, LIU Yuanxi, JIN Hongyu, MA Shuangcheng. Determination of residual solvents in extract of Coleus amboinicus by headspace-gas chromatography [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 295-299.
[10]	WANG Changshun, WANG Xiaolei, DUAN Jiping, YUAN Hao, LIU Yongli, ZHAO Ding. Effect of sulfur fumigation on quality of Angelica dahurica and alternative processing methods in producing areas [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 355-360.
[11]	JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
[12]	ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
[13]	XU Meibao, PEI Yusheng, Liu Yadan, CHEN Chen, DU Ying, LI Wenlong, LIU Tao, CAI Tong. Comparative study of bacterial endotoxin capability verification project at China and abroad [J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1113-1117.
[14]	FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24.
[15]	WANG Xiang, SUN Shuai, WANG Xinguo, NIU Liying. Quantitative transfer relationships of Rubia yunnanensis Diels formula granules based on standard decoctions [J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 891-898.